Skip to main content
Premium Trial:

Request an Annual Quote

Sage Bionetworks, Ingenuity Agree to Share Pathway Data, Algorithms


Ingenuity Systems said this week that it is collaborating with Sage Bionetworks to improve the non-profit's predictive disease networks.

Under the collaboration, Sage will use the company's Ingenuity Pathway Analysis software and Ingenuity Knowledge Base to improve its predictive disease networks. In addition, Sage's web portal will link out to the Ingenuity Knowledge Base and to IPA, and Sage's content, algorithms, and predictive disease networks will be made available within Ingenuity products like IPA.

Ingenuity said that the collaboration will be of particular interest to researchers "who are working to understand the complex developments in the diagnosis, treatment, and etiology of diseases." In particular, using Sage's content and algorithms within IPA will enable users "to more rapidly identify and prioritize therapeutic targets for drug development and assess toxicity of potential drug candidates," the company said.

The collaboration with Sage marks the third partnership that Ingenuity has signed within the last month. In late October, the company announced that it was going to integrate IPA with TransMed Systems' XB Bio-Integration Suite (BI 10/22/2010). In early November, it announced an agreement with Geospiza to integrate IPA with Geospiza's Genesifter (BI 11/5/2010).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more